Literature DB >> 3047854

The role of antibiotics in Campylobacter pylori associated peptic ulcer disease.

E Bayerdörffer1, R Ottenjann.   

Abstract

Since the recognition and first culture of Campylobacter pylori (Cp) the hypothesis of a pathogenic role has been strengthened by numerous investigations. Its close association with active chronic gastritis and even active duodenitis, and the disappearance of these pathologic conditions with antimicrobial treatment suggest a pathogenic role for Cp in active chronic gastritis. The close association of antral gastritis with duodenal ulcer (DU) suggests that Cp associated active chronic gastritis may be an important precondition for the development of DU. Therapy studies so far using either bismuth, antibiotics, or a combination of both could demonstrate that the healing of DU ulcer was closely related to the clearance of Cp and healing of gastritis. Relapse of DU was closely associated with reappearance of Cp and active chronic gastritis. At the present state the combination of bismuth salts and antibiotics has achieved the highest eradication rates of Cp and thus lowest relapse rates of DU. Antibiotics therefore seem to be an indispensable factor in the antimicrobial treatment of Cp associated diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047854

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  18 in total

1.  Helicobacter pylori in dyspeptic patients in Kuwait.

Authors:  D P Britt; M H Barakat; M F Tungekar; S M Painchaud; M Adlouni; K Kern; L Malhas
Journal:  J Clin Pathol       Date:  1990-12       Impact factor: 3.411

2.  Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model.

Authors:  A Lozniewski; A Duprez; C Renault; F Muhale; M C Conroy; M Weber; A Le Faou; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori.

Authors:  S J van Zanten; J Goldie; J Hollingsworth; C Silletti; H Richardson; R H Hunt
Journal:  J Clin Pathol       Date:  1992-03       Impact factor: 3.411

4.  Receptor-mediated adherence of Campylobacter pylori to mouse Y-1 adrenal cell monolayers.

Authors:  D G Evans; D J Evans; D Y Graham
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

5.  In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection.

Authors:  T Kanamaru; Y Nakano; Y Toyoda; K I Miyagawa; M Tada; T Kaisho; M Nakao
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 6.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

7.  Synthesis of terpenoid oxo derivatives with antiureolytic activity.

Authors:  Agata Kozioł; Katarzyna Macegoniuk; Ewa Grela; Agnieszka Grabowiecka; Monika Biernat; Stanisław Lochyński
Journal:  Mol Biol Rep       Date:  2018-10-22       Impact factor: 2.316

8.  In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion.

Authors:  C C Knapp; M D Ludwig; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.

Authors:  G J Malanoski; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

Review 10.  Indications for treatment of Helicobacter pylori infection: a systematic overview.

Authors:  S J Veldhuyzen van Zanten; P M Sherman
Journal:  CMAJ       Date:  1994-01-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.